Ventyx announces Phase 2a study of VTX3232 accomplished primary objective

Ventyx Biosciences (VTYX) announced positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage Parkinson’s disease. The study accomplished the primary objective of demonstrating safety and tolerability, with no drug-related treatment-emergent adverse events observed throughout the dosing period. The trial also met pharmacokinetic and pharmacodynamic endpoints, demonstrating high drug exposures in plasma and cerebral spinal fluid as well as clear evidence of target engagement in plasma and CSF, with potent suppression of NLRP3-related biomarkers. Key takeaways from the Phase 2a study in Parkinson’s patients: “VTX3232 demonstrated an excellent pharmacokinetic profile… VTX3232 was safe and well tolerated through the 28-day dosing period… VTX3232 demonstrated target engagement by decreasing biomarkers of NLRP3 inhibition, IL-1beta in plasma and IL-18, in both the plasma and CSF… VTX3232 treatment was associated with improvement in both motor and non-motor symptoms of Parkinson’s disease, as measured by MDS-UPDRS…No acute changes in exploratory PET imaging were observed, consistent with a relatively short, 28-day study”